|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0002555,
umls-concept:C0006141,
umls-concept:C0006142,
umls-concept:C0008976,
umls-concept:C0012634,
umls-concept:C0019932,
umls-concept:C0034656,
umls-concept:C0039286,
umls-concept:C0087111,
umls-concept:C0232970,
umls-concept:C1257890,
umls-concept:C1516213,
umls-concept:C1522673,
umls-concept:C1527249,
umls-concept:C2603343
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2003-3-14
|
|
pubmed:abstractText |
To determine whether the addition of aminoglutethimide to tamoxifen is able to improve the outcome in postmenopausal patients with hormone receptor-positive, early-stage breast cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:FridrikMichaelM,
pubmed-author:GnantMichaelM,
pubmed-author:HaiderKarinK,
pubmed-author:HausmaningerHubertH,
pubmed-author:JakeszRaimundR,
pubmed-author:KubistaErnstE,
pubmed-author:KwasnyWernerW,
pubmed-author:MenzelChristianC,
pubmed-author:MlineritschBrigitteB,
pubmed-author:SamoniggHellmutH,
pubmed-author:SchmidMarianneM,
pubmed-author:SeifertMichaelM,
pubmed-author:StegerGüntherG,
pubmed-author:SteindorferPeterP,
pubmed-author:StiererMichaelM,
pubmed-author:TaucherSusanneS,
pubmed-author:TauschChristophC,
pubmed-author:WetteViktorV
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
984-90
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:12637461-Aged,
pubmed-meshheading:12637461-Aminoglutethimide,
pubmed-meshheading:12637461-Antineoplastic Agents, Hormonal,
pubmed-meshheading:12637461-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12637461-Austria,
pubmed-meshheading:12637461-Breast Neoplasms,
pubmed-meshheading:12637461-Chemotherapy, Adjuvant,
pubmed-meshheading:12637461-Disease Progression,
pubmed-meshheading:12637461-Drug Administration Schedule,
pubmed-meshheading:12637461-Estrogen Receptor Modulators,
pubmed-meshheading:12637461-Female,
pubmed-meshheading:12637461-Humans,
pubmed-meshheading:12637461-Middle Aged,
pubmed-meshheading:12637461-Neoplasm Recurrence, Local,
pubmed-meshheading:12637461-Neoplasm Staging,
pubmed-meshheading:12637461-Neoplasms, Second Primary,
pubmed-meshheading:12637461-Postmenopause,
pubmed-meshheading:12637461-Receptors, Estrogen,
pubmed-meshheading:12637461-Receptors, Progesterone,
pubmed-meshheading:12637461-Survival Analysis,
pubmed-meshheading:12637461-Tamoxifen,
pubmed-meshheading:12637461-Treatment Outcome
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.
|
|
pubmed:affiliation |
Medical Department, Graz University, and Second Department of Surgery, Graz Hospital, Graz, Austria. marianne.shmid@kfunigraz.ac.at
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|
